<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) in children has been previously treated with high dose <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="2" ids="8378">prednisolone</z:chebi> (HDMP) with favorable results </plain></SENT>
<SENT sid="1" pm="."><plain>We reviewed our experience with intravenous HDMP </plain></SENT>
<SENT sid="2" pm="."><plain>Seven children with a diagnosis of SAA confirmed on bone marrow biopsy were treated with 300 mg/kg total dose of intravenous HDMP over a 4 week period </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were closely monitored for response and side effects </plain></SENT>
<SENT sid="4" pm="."><plain>HDMP was well tolerated except for <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> in one case </plain></SENT>
<SENT sid="5" pm="."><plain>Six of the seven patients showed no response to HDMP </plain></SENT>
<SENT sid="6" pm="."><plain>This observation is in stark contrast with previous trials on use of HDMP in SAA </plain></SENT>
<SENT sid="7" pm="."><plain>It is concluded that HDMP should be reserved only for patients with milder <z:hpo ids='HP_0005528'>bone marrow hypoplasia</z:hpo> </plain></SENT>
</text></document>